

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

DRAFT ICCVAM TEST METHOD RECOMMENDATIONS

**Assessment of the Use of the LLNA to Address Relative Skin
Sensitization Potency**

January 2008

15 **1.0 Draft Recommendations: Test Method Uses and Limitations**

16 *Background:* ICCVAM is currently evaluating the validation status of the LLNA for the
17 classification of skin sensitization potency. The information included in this BRD is
18 based on a retrospective review of LLNA, guinea pig, and human data derived from a
19 database of over 500 substances, 170 of which have comparative LLNA, guinea pig,
20 and/or human data. Among these 170 substances, there are 112 substances with
21 comparative human data (97 sensitizers, 15 non-sensitizers), 105 substances with
22 comparative guinea pig data (52 sensitizers, 53 non-sensitizers), and 47 substances with
23 comparative human and guinea pig data (34 sensitizers, 13 non-sensitizers). The
24 performance of the LLNA, using LLNA EC3 values, was evaluated against the potency
25 classification assigned based on either human or guinea pig data.

26 *Draft Recommendations:*

27 *Using LLNA Data to Predict Human Potency Classification Categories (i.e., Strong vs.*
28 *Weak¹):* Based on this analysis, there is a significant positive correlation ($p < 0.0001$)
29 between EC3 values and human threshold values used to distinguish strong from weak
30 sensitizers. An accuracy analyses was conducted using a range of LLNA EC3 values
31 versus human threshold concentrations using either $\leq 250 \mu\text{g}/\text{cm}^2$ or $\leq 500 \mu\text{g}/\text{cm}^2$ as the
32 threshold for discriminating between strong and weak human sensitizers. However, this
33 correlation is not very strong, as evidenced by $R^2=0.405$. The data suggest that there is
34 only a small difference in accuracy when the human threshold concentration for
35 distinguishing weaker sensitizers from strong sensitizers is $\leq 250 \mu\text{g}/\text{cm}^2$ or ≤ 500
36 $\mu\text{g}/\text{cm}^2$. The LLNA EC3 threshold values that provide optimal (albeit modest)
37 classification when compared to either of the two proposed human threshold values (\leq
38 $250 \mu\text{g}/\text{cm}^2$ and $\leq 500 \mu\text{g}/\text{cm}^2$) were 6.8% and 8.1%, respectively. Using these two EC3
39 values, the correct classification rate was 74% (60/81) and 70% (57/81) for 250 and 500
40 $\mu\text{g}/\text{cm}^2$, respectively, while the over- and under-classification rates ranged from 28%
41 (10/36) to 31% (9/29) and 24% (11/45) to 29% (15/52), respectively.

¹ Although the skin sensitization categories proposed by the GHS (United Nations Globally Harmonized System for the Labelling and Classification of Chemicals) are Category 1: Strong Sensitizer and Category 2: Sensitizer, to avoid confusion in this document these are instead referred to as "strong" and "weak" sensitizers.

42 When substances incorrectly identified as false positive or false negative in the LLNA
43 (when compared to highest accuracy for human data) are included in these analyses, as
44 well as those classified as non-sensitizers in both the LLNA and in humans, the optimal
45 EC3 value was 9.4% for either human threshold concentration. Using all 112 substances
46 with both LLNA and human data, the correct classification rate was 62% (70/112) and
47 60% (67/112) for 250 and 500 $\mu\text{g}/\text{cm}^2$, respectively, while the over- and under-
48 classification rates ranged from 26% (13/50) to 33% (5/15) and 21% (10/47) to 33%
49 (14/43), respectively.

50 *Using LLNA Data to Predict Guinea Pig Potency Classification Categories (i.e., Strong*
51 *vs. Weak):* Based on this limited dataset, there does not appear to be a significant
52 association between LLNA EC3 values and sensitization potency based on guinea pig
53 data. In one analysis, which focused only on substances classified as sensitizers in both
54 the LLNA and in guinea pigs, overclassification means that weak sensitizers are
55 misclassified as strong while underclassification means that strong sensitizers are
56 misclassified as weak. Using the optimal EC3 value of 2.0%, the correct classification
57 rate was 73% (38/52), while the over- and under-classification rates were 28% and 26%,
58 respectively. In a second analysis, which included substances classified as sensitizers in
59 both the LLNA and in humans as well as substances classified in the LLNA as false
60 positives and false negatives compared to the human, and substances classified as non-
61 sensitizers in both the LLNA and in humans. In this analysis, overclassification means
62 that nonsensitizers are misclassified as weak or strong sensitizers and weak sensitizers are
63 misclassified as strong while underclassification means that strong sensitizers are
64 misclassified as weak or nonsensitizers and weak sensitizers are misclassified as
65 nonsensitizers. Using the optimal EC3 value of 3.6%, the correct classification rate was
66 57% (60/105), while the over- and under-classification rates ranged from 25% (8/32) to
67 61% (30/49) and 9% (3/32) to 17% (4/24), respectively.

68 Considered together, these data indicate that although there is a significant positive
69 correlation between LLNA EC3 values and human sensitization threshold doses, this
70 correlation is not strong. Therefore, the LLNA should not be considered as stand-alone
71 test method for predicting sensitization potency, but must instead be used as part of a
72 weight-of-evidence evaluation to discriminate between strong and weak sensitizers.

73 **2.0 Draft Recommendations: Test Method Protocol for the LLNA**

74 The ICCVAM recommended LLNA protocol, which is based on recommendations from
75 an independent expert peer review panel evaluation of the LLNA (ICCVAM 1999), can
76 be found on the ICCVAM-NICEATM website at
77 <http://iccvam.niehs.nih.gov/methods/immunotox/llnados/LLNAProt.pdf> (ICCVAM
78 2001). The LLNA procedure is also described in the EPA Health Effects Test Guidelines
79 (EPA 2003) and OECD TG 429 (OECD 2002). Although not included in these protocols,
80 a description of how to calculate an EC3 is included in the draft ICCVAM LLNA
81 performance standards
82 (<http://iccvam.niehs.nih.gov/methods/immunotox/PerfStds/LLNAPerfStd07Jan08FD.pdf>)

83 **3.0 Draft Recommendations: Future Studies**

84 To further evaluate the usefulness and limitations of the LLNA for potency
85 determinations, efforts should be made to identify additional human data and human
86 experience and guinea pig data for substances with comparative LLNA data. Emphasis
87 should be placed on identifying substances that are classified as strong sensitizers based
88 on a threshold concentration between 250 $\mu\text{g}/\text{cm}^2$ to 500 $\mu\text{g}/\text{cm}^2$ to more adequately
89 evaluate the usefulness and limitations of choosing one of these two reference thresholds
90 that have been proposed.

91